We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Amarin's heart drug Vascepa is casting its net with a first-ever TV ad campaign. Although the triglyceride-lowering drug has been on the market for five years, Amarin is anticipating cardiovascular outcomes data this fall—and if the trial comes up positiv
Zacks Investment Research lowered shares of Amarin (NASDAQ:AMRN) from a hold rating to a sell rating in a research report sent to investors on Wednesday.